Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial

Open access
Teng, Edmond, Manser, Paul T., Pickthorn, Karen, Brunstein, Flavia, Blendstrup, Mira, Sanabria Bohorquez, Sandra, Wildsmith, Kristin R., Toth, Bali, Dolton, Michael, Ramakrishnan, Vidya, Bobbala, Ashwini, Sikkes, Sietske A. M., Ward, Michael, Fuji, Reina N., Kerchner, Geoffrey A., Tauriel Investigators, Farnbach, Peter, Kyndt, Chris, O'Brien, Terence, Yassi, Nawaf, Schwartz, Raymond, Lieten, Siddhartha, Vandenberghe, Rik, Vanhee, Frederik, Bergeron, Richard, Black, Sandra, Cohen, Sharon, Frank, Andrew, Nisker, William, Tartaglia, Maria Carmela, Justesen, Annette, Alexandersen, Peter, Nielsen, Soren, Areovimata, Anna, Anthony, Pierre, Belliard, Serge, Blanc, Frédéric, Ceccaldi, Mathieu, Dubois, Bruno, Krolak-Salmon, Pierre, Mollion, Hélène, Pasquier, Florence, Grimmer, Timo, Kottke-Arbeiter, Monika Elisabeth, Laske, Christoph, Peters, Oliver, Polivka, Dörte, von Arnim, Christine, Bruno, Giuseppe, De Lena, Carlo, Cassetta, Emanuele, Centonze, Diego, Logroscino, Giancarlo, Dautzenberg, Paul, Rutgers, Sterre, Prins, Niels, Czarnecki, Maciej, Dobryniewski, Jacek, Ilkowski, Jan, Klodowska, Gabriela, Krygowska-Wajs, Anna, Kucharski, Robert, Mickielewicz, Anatol, Ratajczak, Marcin, Zboch, Marzena, Zielinski, Tomasz, Abizanda Soler, Pedro, Agüera Morales, Eduardo, Baquero Toledo, Miquel, Blesa González, Rafael, Boada Rovira, Mercè, Del Olmo Rodriguez, Antonio, Krupinski, Jerzy, Linazasoro Cristobal, Gurutz, López Arrieta, Jesús, Riverol Fernandez, Mario, Sanchez Del Valle Diaz, Raquel, Viñuela Fernandez, Félix, Jonsson, Michael, Östlund, Henrik, MacSweeney, Josephine Emer, Mummery, Catherine, Agronin, Marc, Ala, Thomas, Bond, Wendy, Schaerf, Frederick, Brody, Mark, Edwards, Keith, Forchetti, Concetta, Sood, Ajay, Geldmacher, David, Goldstein, Mark, Goodman, Ira, Hart, David, Honig, Lawrence, Justiz, William, Levey, Allan, Losk, Scott, Marshall, Gad, Martinez, Walter, McAllister, Peter, McElveen, William Alvin, Maldonado-Robles, Orlando, Murphy, Cynthia, Nair, Malini, Nair, Anil, Omidvar, Omid, Oskooilar, Nader, Porsteinsson, Anton, Rosenbloom, Michael, Russell, David, Sajjadi, Seyed Ahmad, Pierce, Aimee, Salloway, Stephen, Sha, Sharon, Shah, Raj, Sharma, Sanjiv, Smith, William, Stein, Lee, Stoukides, John, Thein, Stephen, Turner, Raymond, Watson, David, Weisman, David · 2022 · JAMA Neurology

Abstract

Importance: Neurofibrillary tangles composed of aggregated tau protein are one of the neuropathological hallmarks of Alzheimer disease (AD) and correlate with clinical disease severity. Monoclonal antibodies targeting tau may have the potential to ameliorate AD progression by slowing or stopping the spread and/or accumulation of pathological tau. Objective: To evaluate the safety and efficacy of the monoclonal anti-tau antibody semorinemab in prodromal to mild AD. Design, Setting, and Participants: This phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted between October 18, 2017, and July 16, 2020, at 97 sites in North America, Europe, and Australia. Individuals aged 50 to 80 years (inclusive) with prodromal to mild AD, Mini-Mental State Examination scores between 20 and 30 (inclusive), and confirmed β-amyloid pathology (by positron emission tomography or cerebrospinal fluid) were included. Interventions: During the 73-week blinded study period, participants received intravenous infusions of placebo or semorinemab (1500 mg, 4500 mg, or 8100 mg) every 2 weeks for the first 3 infusions and every 4 weeks thereafter. Main Outcomes and Measures: The primary outcomes were change from baseline on the Clinical Dementia Rating-Sum of Boxes score from baseline to week 73 and assessments of the safety and tolerability for semorinemab compared with placebo. Results: In the modified intent-to-treat cohort (n = 422; mean [SD] age, 69.6 [7.0] years; 235 women [55.7%]), similar increases were seen on the Clinical Dementia Rating-Sum of Boxes score in the placebo (n = 126; Δ = 2.19 [95% CI, 1.74-2.63]) and semorinemab (1500 mg: n = 86; Δ = 2.36 [95% CI, 1.83-2.89]; 4500 mg: n = 126; Δ = 2.36 [95% CI, 1.92-2.79]; 8100 mg: n = 84; Δ = 2.41 [95% CI, 1.88-2.94]) arms. In the safety-evaluable cohort (n = 441), similar proportions of participants experienced adverse events in the placebo (130 [93.1%]) and semorinemab (1500 mg: 89 [88.8%]; 4500 mg: 132 [94.7%]; 8100 mg: 90 [92.2%]) arms. Conclusions and Relevance: In participants with prodromal to mild AD in this randomized clinical trial, semorinemab did not slow clinical AD progression compared with placebo throughout the 73-week study period but did demonstrate an acceptable and well-tolerated safety profile. Additional studies of anti-tau antibodies may be needed to determine the clinical utility of this therapeutic approach. Trial Registration: ClinicalTrials.gov Identifier: NCT03289143.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaneurol.2022.1375

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 202

Metadata

Authors
Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blendstrup, M., Sanabria Bohorquez, S., Wildsmith, K. R., Toth, B., Dolton, M., Ramakrishnan, V., Bobbala, A., Sikkes, S. A. M., Ward, M., Fuji, R. N., Kerchner, G. A., Tauriel Investigators, Farnbach, P., Kyndt, C., O'Brien, T., Yassi, N., Schwartz, R., Lieten, S., Vandenberghe, R., Vanhee, F., Bergeron, R., Black, S., Cohen, S., Frank, A., Nisker, W., Tartaglia, M. C., Justesen, A., Alexandersen, P., Nielsen, S., Areovimata, A., Anthony, P., Belliard, S., Blanc, F., Ceccaldi, M., Dubois, B., Krolak-Salmon, P., Mollion, H., Pasquier, F., Grimmer, T., Kottke-Arbeiter, M. E., Laske, C., Peters, O., Polivka, D., von Arnim, C., Bruno, G., De Lena, C., Cassetta, E., Centonze, D., Logroscino, G., Dautzenberg, P., Rutgers, S., Prins, N., Czarnecki, M., Dobryniewski, J., Ilkowski, J., Klodowska, G., Krygowska-Wajs, A., Kucharski, R., Mickielewicz, A., Ratajczak, M., Zboch, M., Zielinski, T., Abizanda Soler, P., Agüera Morales, E., Baquero Toledo, M., Blesa González, R., Boada Rovira, M., Del Olmo Rodriguez, A., Krupinski, J., Linazasoro Cristobal, G., López Arrieta, J., Riverol Fernandez, M., Sanchez Del Valle Diaz, R., Viñuela Fernandez, F., Jonsson, M., Östlund, H., MacSweeney, J. E., Mummery, C., Agronin, M., Ala, T., Bond, W., Schaerf, F., Brody, M., Edwards, K., Forchetti, C., Sood, A., Geldmacher, D., Goldstein, M., Goodman, I., Hart, D., Honig, L., Justiz, W., Levey, A., Losk, S., Marshall, G., Martinez, W., McAllister, P., McElveen, W. A., Maldonado-Robles, O., Murphy, C., Nair, M., Nair, A., Omidvar, O., Oskooilar, N., Porsteinsson, A., Rosenbloom, M., Russell, D., Sajjadi, S. A., Pierce, A., Salloway, S., Sha, S., Shah, R., Sharma, S., Smith, W., Stein, L., Stoukides, J., Thein, S., Turner, R., Watson, D., & Weisman, D.
Venue
JAMA Neurology
Published
2022-08-01
Volume
79
Issue
8
Pages
758
ISSN
2168-6149 (ISSN-L)
OpenAlex
W4282547758
Cited by
202
References
14
FWCI
20.92
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jamaneurol.2022.1375
The paper
Teng, E., Manser, P. T., Pickthorn, K., Brunstein, F., Blendstrup, M., Sanabria Bohorquez, S., Wildsmith, K. R., Toth, B., Dolton, M., Ramakrishnan, V., Bobbala, A., Sikkes, S. A. M., Ward, M., Fuji, R. N., Kerchner, G. A., Tauriel Investigators, Farnbach, P., Kyndt, C., O'Brien, T., . . . Weisman, D. (2022). Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2022.1375

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.